Reuters: Regulatory News: Eli Lilly to stop developing schizophrenia drug

Reuters: Regulatory News Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com

Eli Lilly to stop developing schizophrenia drug Aug 29th 2012, 12:16 Wed Aug 29, 2012 8:16am EDT Aug 29 (Reuters) - Eli Lilly and Co said it would stop developing an experimental schizophrenia drug after a recent analysis showed that a late-stage trial on the drug was likely to fail. Lilly said that an independent futility analysis concluded the second late-stage study on the drug was unlikely to meet the main goal of the trial. Additionally, another mid-stage trial, which was testing the drug -- pomaglumetad methionil, or mGlu2/3 -- as an adjunctive treatment with atypical antipsychotics, also failed to meet the main study goal.

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions